Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: Association with a particular immunophenotype of blast cells

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3547-3556

  Kraguljac Kurtović, Nada ^b   Krajnović, Milena ^a   Bogdanović, Andrija ^b,c   Suvajdžić, Nada ^b,c   Jovanović, Jelica ^b   Dimitrijević, Bogomir ^a   Čolović, Milica ^b,c   Krtolica, Koviljka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Acute myeloid leukemia; Immunophenotype; Methylation profile; MGMT; p15 INK4B

Indexed keywords

CD15 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P15; STEM CELL FACTOR RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVERSE OUTCOME; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MYELOID PROGENITOR CELL; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; FLOW CYTOMETRY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84880318466     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0289-6     Document Type: Article

References (56)

1. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-9.
2. Rush LJ, Plass C. Alterations of DNA methylation in hematologic malignancies. Cancer Lett. 2002;185:1-12.
3. Esteller M. Profiling aberrant methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol. 2003;109:80-8.
4. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 2006;29:1-13.
5. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol. 2007;138:3-11.
6. Schoofs T, Müler-Tidow C. DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat Rev. 2011;37:S13-8.
7. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730-40.
8. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JPJ. Methylation profiling in acute myeloid leukemia. Blood. 2001;97:2823-9.
9. Galm O, Wilop S, Luders C, Jost E, Gehbauer G, Herman JG, Osieka R. Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia. Ann Hematol. 2005;84:39-46.
10. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15INK4b and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leukemia Res. 2005;29:653-9.
11. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B1. Cancer Res. 1996;56:722-7.
12. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-12.
13. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberf AP, Cui H. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature. 2008;451:202-6.
14. Visser KE, Kast WM. Effects of TGF-β on the immune system: implications for early detection and prevention. Lancet Oncol. 2002;3:755-63.
15. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003;63:1114-21.
16. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol. 2002;9:2388-99.
17. Margison GP, Povey AC, Kaina B, Santibanez-Koref MF. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis. 2003;24:625-35.
18. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltrasferase in human cancer. Oncogene. 2004;23:1-8.
19. Bogdanović G, Jurišić V, Kraguljac N, Mrdjanović J, Jakimov P, Krtolica K, Krajnović M, Magić Z, Stojiljković B, Andrijević LJ, Srdić T, Baltić M, Popović S. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy - related myelodysplastic syndrome. Leukemia Res. 2007;31:1105-13.
20. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-7.
21. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, Baylin SB, Herman JG. Hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Nat Cancer Inst. 2002;94:26-32.
22. Kraguljac Kurtović N, Krajnović M, Dimitrijević B, Mihaljević B, Gotić M, Krtolica K. Frequency of aberrant promoter methylation of p15INK4B and O6-methylguanine-DNA methyltransferase genes in B-cell non-Hodgkin lymphoma: a pilot study. Arch Biol Sci. 2010;62:211-21.
23. Lenz G, Hutter G, Hiddemann W, Dreyling M. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol. 2004;83:628-33.
24. Chim CS, Kwong YL. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. Leuk Lymphoma. 2006;47:815-25.
25. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.
26. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
27. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311-8.
28. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biond A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-9.
29. Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21(Suppl 97):77-89.
30. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-95.
31. Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussic SJ, Oldaker T, Shenkin M, Stone E, Wallace P. 2006 Bethesda international consensus recommendation on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytom B Clin Cytom. 2007;72(Suppl 1):S14-22.
32. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB, European Group for the Immunological Characterization of Leukaemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9:1783-6.
33. Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza Ludwig WD, Matutes E, Orfao A, Sperling C, van't Veer MB, European Group for the Immunological Characterization of Leukaemias (EGIL). The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood. 1998;92:596-9.
34. Novak A, Kruškić M, Ludoški M, Jurukovski V. Rapid method for obtaining high-quality chromosome banding in the study of hematopoietic neoplasia. Cancer Genet Cytogenet. 1994;74:109-14.
35. Shaffer LG, Tommerup N, editors. ISCN 2005: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005.
36. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council adult and children's leukaemia working parties. Blood. 1998;92:2322-33.
37. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
38. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-6.
39. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucl Acids Res. 2001;29:e65.
40. Krtolica K, Krajnović M, Ušaj-Knežević S, Babić D, Jovanović D, Dimitrijević B. Comethylation of p16 and MGMT genes in colorectal carcinoma: correlation with clinicopathological features and prognostic value. World J Gastroenterol. 2007;13:1187-94.
41. Mikeska T, Candiloro ILM, Dobrovic A. The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics. 2010;2:561-73.
42. Herman JG, Civin CI, Issa JPJ, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4a characterize the major types of hematological malignancies. Cancer Res. 1997;57:837-41.
43. Cameron EE, Baylin SB, Herman JG. p15INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94:2445-51.
44. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, Karp JE, Herman JG, Carraway HE. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics. 2010;5:590-600.
45. Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16:559-62.
46. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki H, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16:78-85.
47. Tien HF, Tang JL, Tsay W, Liu MC, Lee FY, Wang CH, Chen YC, Shen MC. Methylation of the p15INK4B gene in myelodisplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukemic transformation. Br J Haematol. 2001;112:148-54.
48. Au WY, Fung A, Man C, Ma SK, Wan TS, Liang R, Kwong YL. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol. 2003;120:1062-5.
49. Wada H, Masuda K, Satoh R, Kakugawa K, Ikawa T, Katsura Y, Kawamoto H. Adult T-cell progenitors retain myeloid potential. Nature. 2008;451:768-72.
50. Tien HF, Wang CH. CD7 Positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leuk Lymphoma. 1998;31:93-8.
51. Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, Yagasaki F, Bessyo M, Sakamki H, Dan K, Kuriya S. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol. 2001;115:612-5.
52. Venditti A, Del Poeta G, Buccisano F, Tamburini A, Cox-Fronccilo MC, Aronica G, Bruno A, Del Moro B, Epiceno AM, Battaglia A, Forte L, Postorino M, Cordero V, Santinelli S, Amadori S. Prognostic relevance of the expression of TdT and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998;12:1056-63.
53. Sangfelt O, Erickson S, Heiden CJ, Gustafsson A, Einhorn S, Grander D. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 1999;18:2798-810.
54. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-12.
55. Visser KE, Kast WM. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia. 1999;13:1188-99.
56. Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SMH, Xu W, Minden MD. A phase II study of temozolomide therapy for poor-risk patients aged ≥60 years with acute myeloid leukemia: low levels of MGMT predict for response. Leukemia. 2007;21:821-4.